Pneumococcal vaccine plan for CLL or SLL patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and have a confirmed diagnosis of CLL or SLL
- You have not had any CLL/SLL treatment yet (no chemotherapy or radiation)
- Your estimated life expectancy is more than 24 months
- No recent fever (over 38°C) in the past week, and no active infection or infection needing strong meds in the last 14 days
- Your white blood cell counts are not too low (absolute lymphocyte count at least 500 cells/mm³)
- You haven’t had a pneumococcal vaccine in the last 12 months and you haven’t had certain immune treatments recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
This study is testing whether the Shingrix vaccine (which protects against shingles) works well and is safe in people with chronic lymphocytic leukemia (CLL). The vaccine may help boost your immune system's ability to fight off shingles, a common and painful infection for CLL patients.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.